Evofem Biosciences, Inc.(EVFM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EVFM Evofem Biosciences, Inc.

Trading 03-16 11:43:00 EDT Delay

{"stockData":{"symbol":"EVFM","market":"US","secType":"STK","nameCN":"Evofem Biosciences, Inc.","latestPrice":0.00887,"timestamp":1773675780000,"preClose":0.0087,"halted":0,"volume":9555,"delay":15,"changeRate":0.019540229885057474,"floatShares":113354642,"shares":132530081,"eps":0.000356,"marketStatus":"Trading","change":0.00017,"latestTime":"03-16 11:43:00 EDT Delay","open":0.0087,"high":0.00887,"low":0.0087,"amount":84.7293447,"amplitude":0.01954,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.000356,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773691200000},"marketStatusCode":2,"adr":0,"exchange":"PINK","adjPreClose":0.0087,"volumeRatio":0.116671},"requestUrl":"/m/hq/s/EVFM/wiki","defaultTab":"wiki","newsList":[{"id":"2618910973","title":"Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618910973","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618910973?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:08","pubTimestamp":1773259706,"startTime":"0","endTime":"0","summary":"Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7CtcMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","EVFM"],"gpt_icon":0},{"id":"2618297359","title":"Evofem Reports Fifth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2618297359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618297359?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259502,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA9X1FWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2606729490","title":"Evofem CEO Demands Overhaul of Women’s Health at Fierce JPM Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606729490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606729490?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:10","pubTimestamp":1769411431,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. CEO Saundra Pelletier delivered a powerful keynote address at Fierce JPM Week 2026, calling for a fundamental reset in women’s health. Pelletier highlighted the historical neglect of women’s health issues, stating, “If men suffered from endometriosis, it would be solved by now,” and criticized the exclusion of women from clinical trials due to perceptions about hormonal complexity. She emphasized Evofem’s commitment to prioritizing transparency, education, and respect in their approach to women’s health. The full keynote, titled “Rebuilding Women’s Health from the Ground Up,” is available for on-demand viewing via Fierce Pharma. Register for Fierce JPM Week 2026 and scroll to \"Friday, January 23\" to access the session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL8zZFgY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AWHL","BK4007","EVFM","BK4082","BK4584"],"gpt_icon":0},{"id":"2586423298","title":"Evofem Biosciences Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586423298","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586423298?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:49","pubTimestamp":1764193776,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. held its Annual Meeting of Stockholders on November 26, 2025. Stockholders approved the election of Kim Kamdar, Ph.D., Colin Rutherford, Lisa Rarick, and Tony O'Brien as directors. Approval was also granted for an amendment to the Certificate of Incorporation to authorize a one-time reverse stock split of the company's common stock at a ratio between 1-for-500 and 1-for-1,500, to be implemented at any time before November 26, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLppVzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2583661512","title":"Evofem Biosciences Q3 net sales rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661512","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661512?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:23","pubTimestamp":1763069024,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Q3 net sales riseOverviewEvofem Q3 net sales rise 10% yr/yr to $5.0 mlnCompany posts $1.0 mln operating income, reversing prior yr $2.4 mln lossOperating expenses fall 42% yr/yr, ai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP17R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4584","EVFM"],"gpt_icon":0},{"id":"2583511761","title":"Evofem Biosciences Q3 Pretax Profit USD -1.573 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511761?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXE87230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2577571894","title":"Evofem Biosciences Inc. Announces Date for Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577571894","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577571894?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:53","pubTimestamp":1761000822,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. will hold its 2025 Annual Meeting of Stockholders on [date]. At the meeting, shareholders will vote on several proposals, including the ratification of BPM LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, and a proposal to authorize the Board, at its discretion, to adjourn the Annual Meeting to another place, or to a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the listed proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL2pD03Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2577899181","title":"Evofem Biosciences Inc: Delivered Notice of Termination to Aditxt Notifying That Co Was Exercising Its Right to Terminate Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577899181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577899181?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:59","pubTimestamp":1760997565,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nFWN3VZ02M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","ADTX","BK4584","BK4139","BK4007"],"gpt_icon":0},{"id":"2577893924","title":"Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2577893924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577893924?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:19","pubTimestamp":1760991540,"startTime":"0","endTime":"0","summary":"-- Evofem Shareholders Did Not Approve the Merger with Aditxt --. -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales --. \"With the outcome of this meeting, we are pivoting to focus our efforts on regaining a national listing for Evofem's stock and securing capital to catalyze our growth trajectory and better position us to deliver sustainable positive EBITDA in 2027,\" said Saundra Pelletier, CEO of Evofem Biosciences. \"We are grateful to Aditxt for its support of Evofem and our mission through its meaningful investments, and we look forward to a fruitful  collaboration to commercialize the Mitomic diagnostic tests for women's health conditions , including endometriosis and ovarian cancer, under our September 2024 agreement.\". The Company commercializes two FDA-approved sexual health products: PHEXXI  vaginal gel for hormone-free, on-demand contraception, and SOLOSEC  2 g oral granules, a single dose oral 5-nitroimidazole drug indicated for the t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BV","BK4604","TM","BK4120","BK4099","BK4139","BK4232","R","BK4022","BK4096","BK4555","BK4585","BK4588","EVFM","ADTX","BK4007","03160"],"gpt_icon":1},{"id":"2576606069","title":"Evofem Biosciences Amends Debt Terms with Adjuvant Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2576606069","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576606069?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:06","pubTimestamp":1760731595,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. announced an amendment to its existing agreement with Adjuvant Global Health Technology Fund, adjusting the repayment timeline for certain convertible notes. The updated terms specify that the notes will be due either six months from the amendment date, upon a change of control, or in the event of acceleration. Prepayment is restricted for six months following the amendment unless Adjuvant approves otherwise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely respons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4gp3pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2572531937","title":"Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2572531937","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572531937?lang=en_us&edition=fundamental","pubTime":"2025-10-01 20:47","pubTimestamp":1759322849,"startTime":"0","endTime":"0","summary":"**Evofem Biosciences Inc. Announces Regulatory Filing for SOLOSEC in UAE** San Diego, Oct. 1, 2025 - Evofem Biosciences Inc. has announced that its licensee, Pharma 1, has submitted a regulatory application to the United Arab Emirates  Ministry of Health and Prevention for SOLOSEC  2g oral granules. This marks the first ex-U.S. regulatory filing for SOLOSEC, Evofem's FDA-approved single-dose oral treatment for bacterial vaginosis  and trichomoniasis. Pharma 1, which holds exclusive commercialization rights for SOLOSEC in the Middle East, aims to launch the product in the UAE in the first half of 2026, pending regulatory approval. No grant or funding was announced in connection with this regulatory review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL88mtnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evofem.com","description":"Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.","exchange":"PINK","name":"Evofem Biosciences, Inc.","nameEN":"Evofem Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evofem Biosciences, Inc.(EVFM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evofem Biosciences, Inc.(EVFM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evofem Biosciences, Inc.,EVFM,Evofem Biosciences, Inc.股票,Evofem Biosciences, Inc.股票老虎,Evofem Biosciences, Inc.股票老虎国际,Evofem Biosciences, Inc.行情,Evofem Biosciences, Inc.股票行情,Evofem Biosciences, Inc.股价,Evofem Biosciences, Inc.股市,Evofem Biosciences, Inc.股票价格,Evofem Biosciences, Inc.股票交易,Evofem Biosciences, Inc.股票购买,Evofem Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evofem Biosciences, Inc.(EVFM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evofem Biosciences, Inc.(EVFM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction